Platform Expansion - Non-immunomodulatory
Bladder Dysfunction, Hypertension, Type II Diabetes, Sleep Apnea, COPD
Pre-clinicalActive
Key Facts
Indication
Bladder Dysfunction, Hypertension, Type II Diabetes, Sleep Apnea, COPD
Phase
Pre-clinical
Status
Active
Company
About Galvani Bioelectronics
Galvani Bioelectronics, founded in 2016, is a private joint venture between GSK and Verily Life Sciences (Alphabet) focused on developing precision bioelectronic therapies. Its core technology is an implantable, wirelessly controlled neuromodulation platform designed for minimally invasive delivery to treat chronic diseases, starting with immunomodulatory conditions like Rheumatoid Arthritis. The company is currently in the clinical development stage, enrolling patients for its lead RA program, and represents a convergence of biopharma and tech expertise in the emerging field of bioelectronics.
View full company profile